Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pheochromocytoma × vandetanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 9 Lung Neoplasms 7 Breast Neoplasms 5 Glioma 4 Glioblastoma 4 Neoplasms 3 Gliosarcoma 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Brain Neoplasms 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid cancer, medullary 1 Thyroid Neoplasms 1 Thyroid Diseases 1 Thyroid Cancer, Papillary 1 Small Cell Lung Carcinoma 1 Relapsed Pediatric Solid Tumor 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Precancerous Conditions 1 Pleural Effusion 1 Pheochromocytoma 1

Interventions

3-Iodobenzylguanidine 8 anlotinib 4 Temozolomide 4 lutetium Lu 177 dotatate 3 Phenoxybenzamine 3 Everolimus 3 pegfilgrastim 2 cabozantinib 2 Granulocyte Colony-Stimulating Factor 2 Doxazosin 2 Dexmedetomidine 2 Capecitabine 2 Adrenalectomy 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 veliparib 1 vatalanib 1 vandetanib 1 temsirolimus 1 pentetreotide 1 penpulimab 1 pembrolizumab 1 olaparib 1 lenvatinib 1 lanreotide 1 gallium Ga 68 dotatate 1 fluorodopa F 18 1 fludarabine phosphate 1 belzutifan 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡